$MTVA
MetaVia Inc.

2022 Q4 Form 10-Q Financial Statement

#000155837022017864 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.915M $2.533M
YoY Change -25.8% 22.37%
% of Gross Profit
Research & Development $305.0K $571.0K
YoY Change -84.73% -59.04%
% of Gross Profit
Depreciation & Amortization $1.000K $2.000K
YoY Change -91.67% -83.33%
% of Gross Profit
Operating Expenses $2.220M $571.0K
YoY Change -51.51% -59.04%
Operating Profit -$3.104M
YoY Change -10.39%
Interest Expense -$2.191M $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $7.945M -$9.000K
YoY Change
Pretax Income -$4.676M -$3.113M
YoY Change 2.14% -10.05%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.676M -$3.100M
YoY Change 2.14% -10.43%
Net Earnings / Revenue
Basic Earnings Per Share -$3.50
Diluted Earnings Per Share -$0.61 -$3.50
COMMON SHARES
Basic Shares Outstanding 6.504M 26.66M
Diluted Shares Outstanding 888.7K

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $33.36M $6.356M
YoY Change 103.6% -8.99%
Cash & Equivalents $33.40M $6.400M
Short-Term Investments
Other Short-Term Assets $168.0K $1.198M
YoY Change -14.72% 2395.83%
Inventory
Prepaid Expenses $168.0K $859.0K
Receivables
Other Receivables
Total Short-Term Assets $33.53M $7.554M
YoY Change 102.19% -3.7%
LONG-TERM ASSETS
Property, Plant & Equipment $2.000K $3.000K
YoY Change -98.18% -97.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.000K $3.000K
YoY Change -99.07% -98.71%
TOTAL ASSETS
Total Short-Term Assets $33.53M $7.554M
Total Long-Term Assets $2.000K $3.000K
Total Assets $33.53M $7.557M
YoY Change 99.62% -6.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $708.0K $1.075M
YoY Change -14.7% 12.8%
Accrued Expenses $280.0K $544.0K
YoY Change -78.48% -41.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.78M $1.619M
YoY Change 446.31% -14.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.78M $1.619M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $11.78M $1.619M
YoY Change 435.15% -17.06%
SHAREHOLDERS EQUITY
Retained Earnings -$95.80M -$91.10M
YoY Change 17.07% 17.93%
Common Stock $25.00K $1.000K
YoY Change -7.41% -95.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.75M $5.938M
YoY Change
Total Liabilities & Shareholders Equity $33.53M $7.557M
YoY Change 99.62% -6.44%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$4.676M -$3.100M
YoY Change 2.14% -10.43%
Depreciation, Depletion And Amortization $1.000K $2.000K
YoY Change -91.67% -83.33%
Cash From Operating Activities -$1.807M -$2.359M
YoY Change -37.67% -5.9%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 28.82M -134.0K
YoY Change 123.61% 458.33%
NET CHANGE
Cash From Operating Activities -1.807M -2.359M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 28.82M -134.0K
Net Change In Cash 27.01M -2.493M
YoY Change 187.2% -1.5%
FREE CASH FLOW
Cash From Operating Activities -$1.807M -$2.359M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$1.807M -$2.359M
YoY Change -37.67% -5.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.50
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-14.58
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
888693
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
742810
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
888693
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
734500
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001638287
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
888693
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
888693
CY2022Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.33
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37809
dei Entity Registrant Name
EntityRegistrantName
NeuroBo Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2389984
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Berkeley Street, Office 19th Floor
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02116
dei Trading Symbol
TradingSymbol
NRBO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96420000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
702-9600
dei Security12b Title
Security12bTitle
Common stock
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6503528
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6356000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16387000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
859000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
197000
CY2022Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
339000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
7554000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
16584000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
105000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
110000
CY2022Q3 us-gaap Assets
Assets
7557000
CY2021Q4 us-gaap Assets
Assets
16799000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1075000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
830000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
544000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1301000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
26000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1619000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2157000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45000
CY2022Q3 us-gaap Liabilities
Liabilities
1619000
CY2021Q4 us-gaap Liabilities
Liabilities
2202000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
888693
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
888693
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
97056000
CY2021Q1 nrbo Adjustments To Additional Paid In Capital Transaction Costs In Connection With Equity Financing
AdjustmentsToAdditionalPaidInCapitalTransactionCostsInConnectionWithEquityFinancing
908000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91119000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81828000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
5938000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14597000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7557000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16799000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
571000
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1394000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2473000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4549000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2533000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2070000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6725000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6171000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
3104000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
3464000
us-gaap Costs And Expenses
CostsAndExpenses
9198000
us-gaap Costs And Expenses
CostsAndExpenses
10720000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3104000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3464000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9198000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10720000
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
14000
CY2022Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
9000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
93000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3113000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3461000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9291000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10706000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3113000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3461000
us-gaap Net Income Loss
NetIncomeLoss
-9291000
us-gaap Net Income Loss
NetIncomeLoss
-10706000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-10000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3113000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3460000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9295000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10716000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.50
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-14.58
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
888693
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
742810
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
888693
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
734500
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
7203000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
187000
CY2021Q1 nrbo Stock And Warrants Issued During Period Value
StockAndWarrantsIssuedDuringPeriodValue
10000000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-7000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3324000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
13151000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
180000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
72000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-4000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3921000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
9478000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
107000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
1000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3461000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
6125000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14597000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
207000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-1000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2875000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11928000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
211000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-3000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3303000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
8833000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
218000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3113000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
5938000
us-gaap Net Income Loss
NetIncomeLoss
-9291000
us-gaap Net Income Loss
NetIncomeLoss
-10706000
us-gaap Share Based Compensation
ShareBasedCompensation
636000
us-gaap Share Based Compensation
ShareBasedCompensation
474000
nrbo Increase Decrease In Non Cash Lease Expense
IncreaseDecreaseInNonCashLeaseExpense
8000
nrbo Increase Decrease In Non Cash Lease Expense
IncreaseDecreaseInNonCashLeaseExpense
18000
us-gaap Depreciation
Depreciation
19000
us-gaap Depreciation
Depreciation
36000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-75000
nrbo Increase Decrease In Prepaid Expenses And Deposits
IncreaseDecreaseInPrepaidExpensesAndDeposits
627000
nrbo Increase Decrease In Prepaid Expenses And Deposits
IncreaseDecreaseInPrepaidExpensesAndDeposits
219000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
114000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1646000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-839000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-192000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9905000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12235000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
10000000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
134000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
932000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
72000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-134000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9140000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-10031000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3098000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-7000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16387000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10089000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6356000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6984000
nrbo Modification Of Right Of Use Asset And Associated Lease Liability
ModificationOfRightOfUseAssetAndAssociatedLeaseLiability
62000
nrbo Deferred Issuance Costs Incurred But Not Yet Paid
DeferredIssuanceCostsIncurredButNotYetPaid
205000
nrbo Deferred Issuance Costs Incurred But Not Yet Paid
DeferredIssuanceCostsIncurredButNotYetPaid
25000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6400000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91100000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3100000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3500000
us-gaap Net Income Loss
NetIncomeLoss
-9300000
us-gaap Net Income Loss
NetIncomeLoss
-10700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">the reporting period. The most significant estimates in the Company's condensed consolidated financial statements relate to accrued expenses and the fair value of stock-based compensation and warrant issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgements about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2022Q3 nrbo Royalty Payment Accrued
RoyaltyPaymentAccrued
0
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
30000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
221000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
111000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
110000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-75000
CY2022Q3 nrbo Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
356000
CY2021Q4 nrbo Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
854000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
376000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
94000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
59000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
94000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
544000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1301000
CY2022Q3 nrbo Percentage Of Royalty Payments
PercentageOfRoyaltyPayments
0.025
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5995
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
17.83
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
228235
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
229550
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
32498
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
119.72
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
181.20
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
36493
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
99.62
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
36493
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
99.62
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y9M18D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8236
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
234.37
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.807
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.852
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0172
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0308
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
15000000

Files In Submission

Name View Source Status
0001558370-22-017864-index-headers.html Edgar Link pending
0001558370-22-017864-index.html Edgar Link pending
0001558370-22-017864.txt Edgar Link pending
0001558370-22-017864-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrbo-20220930.xsd Edgar Link pending
nrbo-20220930x10q.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nrbo-20220930xex10d1.htm Edgar Link pending
nrbo-20220930xex10d1001.jpg Edgar Link pending
nrbo-20220930xex31d1.htm Edgar Link pending
nrbo-20220930xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nrbo-20220930_def.xml Edgar Link unprocessable
nrbo-20220930_lab.xml Edgar Link unprocessable
nrbo-20220930_pre.xml Edgar Link unprocessable
nrbo-20220930x10q_htm.xml Edgar Link completed
nrbo-20220930_cal.xml Edgar Link unprocessable